Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wolters-kluwer-health/screening-for-ntrk-rearranged-tumors-using-immunohistochemistry-ldI1mKGeBI
References (7)
-
Basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK gene rearrangements (Fusions) (STARTRK-2) -
A. Drilon, S. Siena, S. Ou, M. Patel, M. Ahn, Jeeyun Lee, T. Bauer, A. Farago, J. Wheler, Stephen Liu, R. Doebele, L. Giannetta, G. Cerea, G. Marrapese, M. Schirru, A. Amatu, K. Bencardino, L. Palmeri, A. Sartore-Bianchi, A. Vanzulli, S. Cresta, S. Damian, M. Duca, E. Ardini, G. Li, J. Christiansen, K. Kowalski, Ann Johnson, Rupal Patel, D. Luo, E. Chow-Maneval, Zachary Hornby, P. Multani, A. Shaw, F. Braud (2017)
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).Cancer discovery, 7 4
-
T. Wiesner, Jié He, R. Yelensky, R. Esteve-Puig, T. Botton, I. Yeh, D. Lipson, G. Otto, K. Brennan, R. Murali, M. Garrido, V. Miller, J. Ross, M. Berger, Alyssa Sparatta, G. Palmedo, L. Cerroni, K. Busam, H. Kutzner, M. Cronin, P. Stephens, B. Bastian (2014)
Kinase fusions are frequent in Spitz tumours and spitzoid melanomasNature Communications, 5
-
I. Yeh, M. Tee, T. Botton, A. Shain, Alyssa Sparatta, A. Gagnon, Swapna Vemula, M. Garrido, K. Nakamaru, T. Isoyama, T. McCalmont, P. Leboit, B. Bastian (2016)
NTRK3 kinase fusions in Spitz tumoursThe Journal of Pathology, 240
-
J. Hechtman, R. Benayed, D. Hyman, A. Drilon, A. Zehir, D. Frosina, M. Arcila, S. Dogan, D. Klimstra, M. Ladanyi, A. Jungbluth (2017)
Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK FusionsThe American Journal of Surgical Pathology, 41
-
A. Drilon, T. Laetsch, S. Kummar, S. DuBois, U. Lassen, G. Demetri, M. Nathenson, R. Doebele, A. Farago, A. Pappo, B. Turpin, A. Dowlati, M. Brose, L. Mascarenhas, N. Federman, J. Berlin, W. El-Deiry, C. Baik, J. Deeken, V. Boni, R. Nagasubramanian, Matthew Taylor, E. Rudzinski, F. Meric-Bernstam, D. Sohal, P. Ma, L. Raez, J. Hechtman, R. Benayed, M. Ladanyi, Brian Tuch, K. Ebata, S. Cruickshank, N. Ku, M. Cox, D. Hawkins, D. Hong, D. Hyman (2018)
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and ChildrenThe New England Journal of Medicine, 378
-
C. Lezcano, A. Shoushtari, C. Ariyan, T. Hollmann, K. Busam (2018)
Primary and Metastatic Melanoma With NTRK FusionsThe American Journal of Surgical Pathology, 42
- Publisher
- Wolters Kluwer Health
- Copyright
- Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
- ISSN
- 1541-2016
- DOI
- 10.1097/PAI.0000000000000708
- Publisher site
- See Article on Publisher Site
Abstract
NTRK-rearranged tumors could be treated using promising anti-TRK–targeted therapies in patients with advanced cancers including melanomas. Different targeted therapies are being developed together with different screening strategies including pan-TRK immunohistochemistry (IHC) as first-line screening strategies. In this technical study, we compared 2 pan-TRK IHC (using A7H6R and EPR17341 clones) in tumor samples of patients with advanced melanomas. IHC-positive cases were studied using NTRK1, NTRK2, and NTRK3 fluorescent in situ hybridization tests. Among 300 melanoma samples, 4 samples were positive using A7H6R IHC, but none using EPR17341. None of the 4 samples were NTRK-rearranged using fluorescent in situ hybridization. Different staining was also noted in nontumor kidney tissue, whereas an NTRK1-rearranged tumor used as positive control was strongly stained with both A7H6R and EPR17341 clones. Future studies including more numerous NTRK-rearranged tumors are required to further study and compare the performances of different pan-TRK clones in the screening of NTRK-rearranged cancers.
Journal
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: Mar 27, 2020